Nov 15 |
Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
|
Nov 13 |
Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver MeetingĀ® 2023
|
Nov 9 |
Chemomab Therapeutics GAAP EPS of $0.017
|
Nov 9 |
Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
|
Nov 6 |
Chemomab Therapeutics receives Nasdaq notice regarding minimum bid price requirement
|
Nov 6 |
Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement
|